Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 20, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were appro.

Business Wire • Feb 20, 2026

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 4, 2026, at 1:10 pm ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and P.

Business Wire • Feb 20, 2026

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success a.

Business Wire • Feb 19, 2026

Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.

Zacks Investment Research • Feb 19, 2026

What's Going With Pulse Biosciences Stock On Monday?

Pulse Biosciences Inc. (NASDAQ: PLSE) stock is trading higher on continued strength after the company on Friday shared clinical data from its nPulse Cardiac Catheter first-in-human feasibility study.

Benzinga • Feb 9, 2026

PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data

Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.

Zacks Investment Research • Feb 9, 2026

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annu.

Business Wire • Feb 6, 2026

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in.

Business Wire • Feb 4, 2026

Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a late-breaking science session and a live case transmission featuring the nPulse Cardiac Catheter integrated with Abbott's EnSiteX™ 3D Mapping System at the 31st Annual AF Symposium 2026 meeting, being held February 5-7 in Bo.

Business Wire • Feb 3, 2026